title: High-dose mannose-binding lectin therapy for Ebola virus infection.
abstract: Mannose-binding lectin (MBL) targets diverse microorganisms for phagocytosis and complement-mediated lysis by binding specific surface glycans. Although recombinant human MBL (rhMBL) trials have focused on reconstitution therapy, safety studies have identified no barriers to its use at higher levels. Ebola viruses cause fatal hemorrhagic fevers for which no treatment exists and that are feared as potential biothreat agents. We found that mice whose rhMBL serum concentrations were increased ≥7-fold above average human levels survived otherwise fatal Ebola virus infections and became immune to virus rechallenge. Because Ebola glycoproteins potentially model other glycosylated viruses, rhMBL may offer a novel broad-spectrum antiviral approach.
authors.affiliation: Program of Developmental Immunology, Department of Pediatrics, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts, USA.
authors.forename: Ian C
authors.initials: IC
authors.lastname: Michelow
authors.forename: Calli
authors.initials: C
authors.lastname: Lear
authors.forename: Corinne
authors.initials: C
authors.lastname: Scully
authors.forename: Laura I
authors.initials: LI
authors.lastname: Prugar
authors.forename: Clifford B
authors.initials: CB
authors.lastname: Longley
authors.forename: L Michael
authors.initials: LM
authors.lastname: Yantosca
authors.forename: Xin
authors.initials: X
authors.lastname: Ji
authors.forename: Marshall
authors.initials: M
authors.lastname: Karpel
authors.forename: Matthew
authors.initials: M
authors.lastname: Brudner
authors.forename: Kazue
authors.initials: K
authors.lastname: Takahashi
authors.forename: Gregory T
authors.initials: GT
authors.lastname: Spear
authors.forename: R Alan B
authors.initials: RA
authors.lastname: Ezekowitz
authors.forename: Emmett V
authors.initials: EV
authors.lastname: Schmidt
authors.forename: Gene G
authors.initials: GG
authors.lastname: Olinger
mesh_terms: D000818:Animals; D000998:Antiviral Agents / Q000008:administration & dosage; D029043:Ebolavirus / Q000276:immunology* / Q000472:pathogenicity*; D019142:Hemorrhagic Fever, Ebola / Q000188:drug therapy* / Q000473:pathology*; D006801:Humans; D007155:Immunologic Factors / Q000008:administration & dosage*; D037601:Mannose-Binding Lectin / Q000008:administration & dosage*; D051379:Mice; D018345:Mice, Knockout; D011994:Recombinant Proteins / Q000008:administration & dosage; D016019:Survival Analysis; D016896:Treatment Outcome
chemical_list: D000998:Antiviral Agents; D007155:Immunologic Factors; D037601:Mannose-Binding Lectin; D011994:Recombinant Proteins